# Theravance Biopharma (TBPH) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/TBPH
## Company Profile
- Ticker: TBPH
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Respiratory
## Stock Data
- Close: 16.92 USD
- Market cap: 803195817.9 USD
- Last updated: 2026-08-12
## Business Overview
### Respiratory Medicines
Theravance Biopharma is a biopharmaceutical company whose principal economic asset is a respiratory medicine commercialized through a collaboration.
### YUPELRI
YUPELRI, or revefenacin, is a once-daily nebulized long-acting muscarinic antagonist for maintenance treatment of chronic obstructive pulmonary disease. Theravance receives collaboration revenue tied to U.S. sales. Following the outcome of the CYPRESS study, the company is winding down that clinical program and restructuring around its commercial asset and remaining strategic opportunities.
## Why The Stock Is Moving

As of Aug 12, 2026, TBPH was little changed and closed at $16.92. No new same-company headline was identified in the current news window.

## Recent News
- 2026-08-10 12:30 EST — [Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/TBPH/theravance-biopharma-inc-reports-second-quarter-2026-financial-results-and-provi-d61c1ffa) — Source: Theravance Biopharma
- 2026-06-29 10:00 EST — [THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT](https://biopharmsignal.com/news/TBPH/theravance-biopharma-enters-into-definitive-agreement-to-be-acquired-by-zymework-7bcac832) — Source: Theravance Biopharma
- 2026-05-07 12:30 EST — [Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/TBPH/theravance-biopharma-inc-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Theravance Biopharma
- 2026-03-19 12:30 EST — [Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/TBPH/theravance-biopharma-inc-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update) — Source: Theravance Biopharma
- 2026-03-03 13:30 EST — [Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions](https://biopharmsignal.com/news/TBPH/theravance-biopharma-reports-phase-3-cypress-study-did-not-meet-primary-endpoint-board-accelerates-strategic-review-and-announces-cost-reduction-actions) — Source: Theravance Biopharma